A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

Condition:   Metastatic Castrate-resistant Prostate (CRPC) Cancer Interventions:   Drug: ODM-201;   Drug: Enzalutamide Sponsor:   Gustave Roussy, Cancer Campus, Grand Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials